Skip to main content
. 2017 Nov 2;25(9):1589–1599. doi: 10.3727/096504017X14897896412027

Figure 5.

Figure 5

Effect of LINC00052 on the Wnt/β-catenin signaling pathway-related factors. (A) The interaction between LINC00052 and β-catenin or methyltransferase SMYD2 was detected by pull-down assay. (B) RIP assay further confirmed the interactions of LINC00052 with β-catenin and SMYD2. (C) The interaction between SMYD2 and β-catenin in LINC00052-overexpressing and -silencing cells was detected by immunoprecipitation (IP) analysis. (D) LLY-507, an inhibitor of SMYD2, was used to treat MGC-803 cells, and thus β-catenin methylation was detected. (E) Recombinant protein methylation reaction was performed to reveal the role of LINC00052 in SMYD2-induced β-catenin methylation. (F) β-Catenin expression was detected in SMYD2-overexpressing and -silencing cells. (G) β-Catenin methylation in LINC00052-overexpressing and -silencing cells. (H) β-Catenin expression was detected in LINC00052-overexpressing and -silencing cells. (I) β-Catenin nuclear import in LINC00052-overexpressing and -silencing cells was assessed. (J) The expression of Wnt target proteins in LINC00052-overexpressing and -silencing cells. (K) SMYD2 and β-catenin methylation level testing in GC and normal samples. ***p < 0.001.